title: The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran.
abstract: BACKGROUND
  Studies have shown dabigatran to be an effective anticoagulant with an acceptable bleeding profile. None the less, these patients do suffer from bleeding complications. Unfortunately, there are currently no direct reversal agents to dabigatran or established guidelines on the management of bleeding in these circumstances.
  
  
  METHODS
  We examined the effects on thrombin generation parameters, after ex-vivo spiking the plasma of patients on dabigatran (n = 8) with FEIBA(®). These parameters were measured using the calibrated automated thrombography (CAT) machine.
  
  
  RESULTS
  In our study, we showed the ability of FEIBA(®) to improve the abnormal thrombin generation parameters caused by dabigatran in these patients.
  
  
  CONCLUSIONS
  This provides evidence, lacking in the literature, that this agent may be able to provide haemostatic support in situations where dabigatran induced coagulopathy exists.
authors.affiliation: Institute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
authors.forename: T-L
authors.initials: TL
authors.lastname: Khoo
authors.forename: C
authors.initials: C
authors.lastname: Weatherburn
authors.forename: G
authors.initials: G
authors.lastname: Kershaw
authors.forename: C J
authors.initials: CJ
authors.lastname: Reddel
authors.forename: J
authors.initials: J
authors.lastname: Curnow
authors.forename: S
authors.initials: S
authors.lastname: Dunkley
mesh_terms: D000991:Antithrombins / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects*; D001778:Blood Coagulation Disorders / Q000188:drug therapy; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D019963:Clinical Chemistry Tests / Q000592:standards*; D000069604:Dabigatran; D006801:Humans; D012107:Research Design; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D001779:Blood Coagulation Factors; D015091:beta-Alanine; C065655:anti-inhibitor coagulant complex; D000069604:Dabigatran